Cangrelor during PCI reduces heart attack risk

“For example, in patients waiting to undergo open-heart surgery, cangrelor (at a lower dose than that used in this study) has been shown to result in consistent platelet inhibition without a significant increase in bleeding,” they reported.

The Medicines Company funded the study. Dr. Bhatt reported that he has received grant money from numerous pharmaceutical companies. He has also received remuneration for lectures, manuscripts and manuscript preparation, and that he holds patents and receives royalties; however, he did not provide details about any of these disclosures.

michele.sullivan@elsevier.com